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Background: The auto-inflammation and phospholipase Cγ2 (PLCγ2)-associated
antibody deficiency and immune dysregulation (APLAID) syndrome is a rare primary
immunodeficiency caused by a gain-of-function mutation S707Y in the PLCG2 gene
previously described in two patients from one family. The APLAID patients presented with
early-onset blistering skin lesions, posterior uveitis, inflammatory bowel disease (IBD) and
recurrent sinopulmonary infections caused by a humoral defect, but lacked circulating
autoantibodies and had no cold-induced urticaria, contrary to the patients with the related
PLAID syndrome.
Case: We describe a new APLAID patient who presented with vesiculopustular rash
in the 1st weeks of life, followed by IBD, posterior uveitis, recurrent chest infections,
interstitial pneumonitis, and also had sensorineural deafness and cutis laxa. Her disease
has been refractory to most treatments, including IL1 blockers and a trial with ruxolitinib
has been attempted.
Results: In this patient, we found a unique de novo heterozygous missense L848P
mutation in the PLCG2 gene, predicted to affect the PLCγ2 structure. Similarly to
S707Y, the L848P mutation led to the increased basal and EGF-stimulated PLCγ2
activity in vitro. Whole blood assays showed reduced production of IFN-γ and IL-17
in response to polyclonal T-cell stimulation and reduced production of IL-10 and IL-1β
after LPS stimulation. Reduced IL-1β levels and the lack of clinical response to treatment
with IL-1 blockers argue against NLRP3 inflammasome hyperactivation being the main
mechanism mediating the APLAID pathogenesis.
Conclusion: Our findings indicate that L848P is novel a gain-of-function mutation that
leads to PLCγ2 activation and suggest cutis laxa as a possible clinical manifestations of
the APLAID syndrome.
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INTRODUCTION
The strict control of inflammation is one of the most important
functions of the immune system (1). While the majority of the
autoimmune inflammatory diseases are mediated by effectors of
the adaptive immune system, auto-inflammatory syndromes are
caused by an aberrant activation of the innate immune cells (1–
4). These disorders are characterized by systemic inflammation
and diverse organ-specific manifestations, such as arthritis,
aseptic meningitis, deafness, or urticaria (4, 5). More than 20
years ago, mutations in the MEFV and TNFRSF1A genes were
shown to cause familial Mediterranean fever and Tumor necrosis
factor receptor-associated periodic syndrome (TRAPS) (6). Since
then, inherited deficiencies in the components of the innate
immune system that control inflammation have been identified,
e.g., cryopyrin-associated periodic syndrome (CAPS) and Auto-
inflammation with infantile enterocolitis (AIFEC) caused by
gain-of-function mutations in NLRP3 and NLRC4 that lead to
the release of pro-inflammatory cytokines (such as IL-1β) (7–
9). These findings expanded the knowledge about mechanisms
mediating auto-inflammation and provided scientific basis for
the targeted treatment of such disorders (4–7).
Phosphatidylinositol and its derivatives are essential
regulators of the human immune cell functions. Phospholipase
C (PLC) is a family of enzymes that catalyze hydrolysis of
phosphatidylinositol 4,5-bisphosphate, producing second
messenger molecules diacylglycerol (DAG) and inositol 1,4,5-
trisphosphate (IP3). IP3 induces release of calcium from
endoplasmic reticulum to the cytoplasm, while DAG can activate
cell signaling proteins, e.g., protein kinase C. PLCγ is structurally
distinct from other PLC enzymes and has two isoforms. PLCγ1
is ubiquitously expressed and acts downstream of growth factor
receptors, while PLCγ2 is found mainly in hematopoietic cells,
where it is activated by tyrosine kinases recruited to immune cell
receptors, e.g., BCR and Fc receptors or, as subsequently shown,
also by Rac GTPase (10–15).
Recently, 27 patients presenting with cold-induced urticaria,
recurrent sinopulmonary infections, antibody deficiency, and
autoimmunity, were found to have heterozygous in-frame
deletions affecting the PLCG2 gene, resulting in constitutive
activation of PLCγ2. This syndrome was designated the PLCγ2-
associated antibody deficiency and immune dysregulation
(PLAID) (10). Thereafter, the auto-inflammation and PLCγ2-
associated antibody deficiency and immune dysregulation
(APLAID) syndrome was described in two patients from
another family (11). APLAID patients presented with early-
onset blistering skin lesions, eye inflammation with ocular
hypertension, inflammatory bowel disease (IBD), arthralgia,
and recurrent sinopulmonary infections caused by a humoral
defect, but lacked circulating autoantibodies and had no cold-
induced urticaria. This distinctive phenotype was caused by a
missense mutation S707Y in the PLCG2 gene that disrupted an
auto-inhibitory cSH2 domain, causing increased production of
intracellular IP3 and calcium release resulting in hyperactivation
of the PLCγ2 signaling pathway (11). Contrary to the PLAID
mutants, this mutation does not lead to constitutive enzymatic
activity, requiring upstream signaling events for its activation.
Here, we report a new patient with APLAID caused by a
unique activating mutation in PLCγ2 that presented with novel
manifestations, including cutis laxa and sensorineural deafness.
MATERIALS AND METHODS
Ethics
All materials were obtained with informed consent in accordance
with the Declaration of Helsinki and with approval from the
ethics committees in Portugal (131/2014) and UK (15/WS/0019).
Written informed consent for publication of this case report was
obtained from the parents of the patient.
Flow Cytometry
For the evaluation of lymphocyte subsets, peripheral blood was
analyzed by Flow Cytometry in a 4-color BD FACS Calibur
(BD, San Jose, California, USA), using the BD IMK kit with
Trucount tubes (BD Biosciences) according to themanufacturer’s
instructions. An additional panel of monoclonal antibodies
(including CD45RA, CD45RO, CD62L, and HLA-DR) was also
performed for further characterization of T-cell differentiation,
using a lyse-wash protocol. Finally, the IOTest R© Beta Mark
kit (Immunotech SAS, a Beckman Coulter Company, Marseille,
France) was also used for the characterization of the TCR Vβ
repertoire.
Flow cytometry data analysis was performed using Multiset
and CellQuestPro software (BD Biosciences).
Proliferation Assays
Proliferative capacity was performed with a thymidine
incorporation assay. In brief, peripheral blood mononuclear
cells (PBMCs) were incubated with mitogens (PHA, final
concentration and PMA+ionomycin) for 3–4 days, and with
antigens (PPD, C. albicans antigen and Tetanus toxoid) for
7–8 days, at 37◦C, in a 5% CO2 atmosphere. The cells were
labeled with tritiated thymidine (3H-thymidine) (Perkin Elmer,
Boston, MA, USA) in the last 18 h of incubation. Cells were then
harvested and transferred to a Filtermat A filter (Perkin Elmer),
and aMeltilex scintillation sheet (Perkin Elmer) was applied after
the Filtermat was dried. The radioactivity in DNA recovered
from the cells was read in a MicroBeta counter (Perkin Elmer).
Results were presented as stimulation indexes, obtained from the
ratios of cpm from stimulated and unstimulated cells (incubated
in parallel).
Antibody Response Evaluation
Immunoglobulins were quantified in serum.
Immunoturbidimetria was used to quantify IgG, IgA, and
IgM. As for specific responses, antibodies for Diphtheria,
Tetanus, and Pertussis were evaluated by ELISA.
Whole-Blood Cytokine Production Assays
Whole blood was diluted 1:5 in RPMI into 96-well
F plates (Corning) and activated using the following
stimulants Phytohemagglutinin (PHA; 10µg/ml; Sigma-
Aldrich) PMA/IONO, LPS (1µg/ml, List Biochemicals),
Pam2CSK4 (Invivogen, 1 micg/ml), Pam3CSK4 (Invivogen,
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1 micg/ml), Flagellin (Invivogen, 1 micg/ml), CL-097
(Invivogen, × micg/ml). Supernatants were taken at 24 h.
Cytokines were measured using multiplexed particle based bead
array (IFNγ, TNFα, IL-17,IL-1b, IL-10, IL-6, R+D Systems
Fluorokinemap) on a Luminex analyser (Bio-Plex, Bio-Rad, UK).
Data were statistically analyzed by the two-tailed Mann-Whitney
test using Prism 6 (GraphPad Software).
Exome Sequencing and Bioinformatics
Analysis
We isolated DNA samples from blood or peripheral blood
mononuclear cells (PBMCs). Library preparation, exome
capture, and sequencing have been done according to the
manufacturers’ instructions. For exome target enrichment
Agilent SureSelect 50Mb kit was used. Sequencing was
done using Illumina HiSeq 2000 with 94 bp paired-end
reads. FASTQ files were aligned to the hg19 reference
sequence using Novoalign version 2.07.19, including hard
and soft clipping, quality calibration and adapter trimming.
Duplicate reads were excluded using the PICARD tool
MarkDuplicates. Calling was performed using SAMtools
v0.18 and single sample calling. The resulting calls were
annotated with the software ANNOVAR. Candidate
variants were filtered based on function: loss-of-function,
non-synonymous or potential splicing altering variants
(defined as being with 5 bp of the actual splice site) and
frequency.
Cell Culture and Transfections
Plasmids for the expression of full-length human pTRIEX-
PLCg2 constructs in mammalian cells have been described
previously (11).
QuikChange PCR mutagenesis (Stratagene) was used to
introduce a pointmutation in the PLCg2WT variant. All mutants
were fully sequenced to verify the fidelity of PCR. COS7cells were
maintained at 37◦C in a humidified atmosphere of 95% air and
5% CO2
In Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen)
supplemented with 10% (v/v) fetal bovine serum (Invitrogen)
and 2.5mM glutamine. Prior to transfection cells were seeded
into 6-well plates at a density of 2.5 × 105 cells/well and grown
for 16 h in 2 ml/well of the same medium. For transfection,
1.0 ug of PLCg2 DNA was mixed with 1 µl of PlusReagentTM
and 7 µl of LipofectamineTM (Invitrogen) and added to the
cells in 0.8ml of DMEM without serum. The cells were
incubated for 3.5 h at 37◦C, 5% CO2 before the transfection
mixture was removed and replaced with DMEM-containing
serum.
FIGURE 1 | (A) Neonatal pustulosis. (B) Cutis laxa. (C) Timeline for the clinical manifestations and treatments of the patient. IRT, Immunoglobulin replacement therapy.
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TABLE 1 | Immunological assessment of the patient.
Immunology 6 Years-old 10 Years-old Reference value
Absolute lymphocyte count (×109/L) 3,600 3,350 2,500–5,500
CD3+(cells/µL) 1,685 1,250 1,200–3,000
CD4+(cells/µL) 985 634 650–1,500
CD4+CD45RA+ (%) 65% 59% 53–86%
CD8+(cells/µL) 640 529 370–1,100
CD8+CD45RA+ (%) 83% 79% 42–82%
CD16+/56+ (cells/µL) 100 143 100–480
CD19+(cells/µL) ↓ 55 ↓ 143 270–860
CD19+CD27-IgD+IgM+ (%) ↑ 90% ↑95% 47–70%
CD19+CD27+ (%) ↓ 6% ↓ 3% 7–24%
CD19+CD27+IgD- (switch) ↓ 0.5% ↓ 0 2.7–12.5%
CD19+CD38+IgMhigh (transitional) ↑ 50% ↑64%
IgG (g/L) 3,563 10.5 (on IRT) 5.3–10.7
IgM (g/L) 0 0 0.46–1.9
IgA (g/L) 0 0 0–1.5
Anti-diphteria 0 2.4 (on IRT) Protective >0.5
Anti-tetanus 0 1.5 (on IRT) Protective >0.5
Proliferative responses to PHA (CPM × 103)
(stimulation index)
25,621 ± 1,762
133
Not performed Control 20,076 ± 3,179
45.8
Proliferative responses to PMA+I (CPM × 103)
(stimulation index)
21,665 + 2,320
75
Not performed Control 13,069 ± 1,645
47.7
Analysis of Inositol Phosphate Formation
in Intact COS7 Cells
Inositol Phosphate formation was assessed as described in
Everett et al. (13). Briefly, 24 h after transfection, the cells were
washed twice with inositol-free DMEM without serum and
incubated for 24 h in 1.5ml of the same medium supplemented
with 0.25% fatty acid free bovine serum albumin (Sigma)
and 1.5 uCi/ml myo-[2−3H]inositol (MP Biomedicals). After
a further 24 h, the cells were incubated in 1.2ml of inositol-
free DMEM without serum containing 20mM LiCl with or
without stimulation with 100 ng/ml EGF (Calbiochem). The
cells were lysed by addition of 1.2ml of 4.5% perchloric
acid. After incubating the samples on ice for 30min, they
were centrifuged for 20min at 3700 × g. Supernatants and
pellets were separated. The supernatants were neutralized by
addition of 3ml of 0.5M potassium hydroxide/9mM sodium
tetraborate and centrifuged for a further 20min at 3700 × g.
Supernatants were loaded onto AG1-X8 200–400 columns (Bio-
Rad) that had been converted to the formate form by addition
of 2M ammonium formate/0.1M formic acid and equilibrated
with water. The columns were washed three times with 5ml
of 60mM ammonium formate/5mM sodium tetraborate, and
inositol phosphates were eluted with 5ml of 1.2M ammonium
formate/ 0.1M formic acid. Fivemilliliter Ultima-Flo scintillation
fluid (PerkinElmer Life Sciences) was added to the eluates
and the radioactivity quantified by liquid scintillation counting.
The values represent total inositol phosphates. The pellets
from the first centrifugation were resuspended in 100 µl of
water and 375 µl of chloroform/methanol/HCl (200:100:15)
was added. The samples were vortexed, and an additional
FIGURE 2 | Reduced production of IL-10 and IL-1β after LPS stimulation;
reduced production of IFN-γ and IL-17 in response to polyclonal T-cell
stimulation (performed at 9, 10, and 11 years-old).
125 µl of chloroform and 125 µl of 0.1M HCl were
added.
After further vortexing, the samples were centrifuged at
700 × g for 10min. Ten microliter of the lower phase
were placed in a scintillation vial with 3ml of Ultima-Flo
scintillation fluid and the radioactivity quantified by liquid
scintillation counting. The obtained values correspond to
radioactivity in inositol lipids. PLC activity is expressed as
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FIGURE 3 | (A,B) De novo L848P mutation in the PLCG2 gene; (C) Leu848 is conserved in most vertebrates; (D) L848P mutation is predicted to affect the PLCγ2
structure while L848F had only minimal impact; (E) Both L848P (3) and S707Y (4) mutants showed increased basal and EGF-stimulated activity in comparison to the
wild-type PLCγ2 (2) and control COS cells (1).
Frontiers in Immunology | www.frontiersin.org 5 December 2018 | Volume 9 | Article 2863
Farela Neves et al. Novel Mutation in PLCG2 Causes APLAID
TABLE 2 | Clinical and immunological manifestations of PLAID patients, previously published APLAID patients and this patient.
PLAID (n = 27) APLAID S707Y (n = 2) APLAID L848P (n = 1)
Genetics heterozygous in-frame deletions PLCG2 gene Missense mutation Missense mutation
Mutation effect Gain-of-function Gain-of-function Gain-of-function
PLCγ2 activation status Constitutive activation Requires upstream signaling for activation Requires upstream signaling
for activation
Affected PLCγ2 domain cSH2 cSH2 spPH
CLINICAL MANIFESTATIONS
Cold urticária X 7
Allergic disease X
Autoimmunity X
Recurrent chest infection X X X
Cutaneous granulomas X X X
Inflammatory bowel disease X X
Posterior uveitis X X
Interstitial pneumonitis X X
Cutis laxa X
Sensorineural deafness X
IMMUNOLOGY
T cells Normal Normal Normal
Class-switched memory B cells
NK cells Normal Normal
IgG Normal
IgA
IgM
Circulating auto antibodies X
the total inositol phosphates formed relative to the amount
of [3H]myo-inositol in the phospholipid pool. Because the
differences in steady state labeling of inositol lipids are
small (within 20%), this normalized PLC activity corresponds
closely to PLC values expressed as total inositol phosphates;
however, the error bars between the duplicates are generally
smaller.
Case Report
Here, we report an 11 years-old girl, second daughter of
healthy non-consanguineous parents of Portuguese origin. She
presented with very severe vesiculo-pustular rash in the 1st
week of life (Figure 1A). Biopsy showed dermis infiltration
by CD68+CD163+S100–CD1a–histiocytes and a presumptive
diagnosis of juvenile xanthogranuloma was made. At the age of
2 months, she started bloody diarrhea and early-onset IBD was
diagnosed based on the endoscopic and histologic findings. The
bowel disease improved after treatment with prednisolone and
maintenance with azathioprine. Nevertheless, she continued to
have recurrent episodes of blistering skin rash and presented
recurrent chest infections. At the age of 3 years she started to
have recurrent eye inflammation that was associated with ocular
hypertension. Systemic xanthogranuloma was suspected and she
was treated with vinblastine, 6-mercaptopurine, methotrexate,
and steroids. Her symptoms did not resolve and she had
more frequent infections, including acute otitis media, recurrent
chronic sinusitis, recurrent pneumonia, and on one occasion,
pulmonary Aspergillus infection that responded to itraconazole.
Cutis laxa was evident since she was 6 years-old (Figure 1B)
and progressive sensorineural deafness was diagnosed at the
age of 7, requiring a hearing-assistive device. Immunological
analysis at that age revealed low IgM and IgA, absent responses
to protein antigens and low B cells, with almost absent class-
switched memory B cells. T-cell proliferation responses were
preserved. No auto-antibodies were found (Table 1). Whole
blood stimulation assays showed a strongly reduced production
of IFN-γ and IL-17 in response to polyclonal T-cell stimulation
and reduced production of IL-10 and IL-1β after LPS stimulation
(Figure 2). However, there was a significant innate induction of
IL-6 and TNFα in response to various TLR agonists including
LPS, PAM 2/3, Flagellin, and CL-097 (Supplementary Figure 1
and Supplementary Table 1 ). She started prophylactic co-
trimoxazole, immunoglobulin replacement, as well as low
dose steroids (5mg every other day) and hydroxychloroquine
(Figure 1C), which led to substantial improvement. Nevertheless,
since the age of 10 years she started to have several relapses
of eye inflammation, skin rash, and pulmonary inflammation
(interstitial pneumonitis) that improved only partially with
high-dose steroids. Anakinra (IL1-receptor antagonist) and
canakinumab (IL1β monoclonal antibody) were tried without
any effect. In view of the excellent results of the use
of JAK inhibitors in auto-inflammatory diseases (16), and
given that PLCγ2 requires upstream signaling events for
its activation, we have very recently decided to treat the
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patient with ruxolitinib as a bridge to hematopoietic stem cell
transplantation.
To uncover genetic basis of the disease, we used whole
exome sequencing and identified a heterozygous missense
L848P mutation in the PLCG2 gene. Sanger sequencing
showed that this mutation appeared de novo in the patient,
while being absent from both parents and a healthy sibling
(Figures 3A,B). The mutation affected amino acid residue
Leu848 in the split pleckstrin homology (spPH) domain of
the PLCγ2 protein that is conserved in most vertebrates
(Figure 3C). The L848P mutation is unique to this patient: it
was never found in humans, e.g., it is absent from more than
120,000 subjects in the gnomAD database (12). Interestingly,
DNA polymorphism rs114618894 that has ∼2% frequency in
Africans affects the same amino acid residue leading to the
L848F substitution. Bioinformatics analysis predicted that the
patient’s mutation L848P was damaging (e.g., SIFT = 0.99,
MutationTaster = 0.99), while L848F was neutral. We used
I-Tasser (17) to model the PLCγ2 protein fragment between
amino acids 770 and 1044 containing the L848P and L848F
substitutions and found that L848P is predicted to affect
the PLCγ2 structure, while L848F had only minimal impact
(Figure 3D). The spPH domain contributes to auto-inhibition
and also binds Rac. A mutation in this domain has been
shown to cause gain of function leading to severe auto-
inflammatory disease in mice (13). Furthermore, an activating
spPH mutation L845F, which is close to residue L848, has
been described in cancer resistance to Ibrutinib, the drug
acting on Btk upstream of PLCγ2 (14). In order to test
the functional effect of the newly found L848P mutation, we
cloned PLCγ2 and introduced by site directed mutagenesis
L848P or the previously reported APLAID mutation S707Y.
We transfected these constructs into COS-7 cells and measured
IP production. In this standard cellular assay, both L848P and
S707Y mutants showed increased basal and EGF-stimulated
activity in comparison to wild-type PLCγ2 (Figure 3E). Taken
together, our data show that L848P is a de novo gain-of-function
mutation that is very likely to have caused the disease in our
patient.
DISCUSSION
Here, we describe a novel patient with the APLAID syndrome
caused by a new missense PLCγ2-activating mutation. This
is only the third reported APLAID patient. The clinical and
immunological manifestations of our patient resembled the
phenotype of the other two APLAID patients described in a
single, previous study (11) with the additional presentation
of sensorineural deafness and cutis laxa (Figure 1C, Table 2).
Interestingly, cutis laxa was also present in two recently identified
Spanish patients with APLAID (18) which suggests that it may
be frequent among APLAID patients. The Plcg2Ali5 mice, with a
gain-of-function missense mutation in the PLCG2 gene, present
inflammatory dermatitis (19). This, and the fact that PLCγ2 is
expressed primarily in hematopoietic cells, makes us speculate
that this new manifestation is probably driven by persistent skin
inflammation.
On the other hand, despite the fact that congenital and peri-
natal causes of sensorineural deafness (infection, malformation,
hypoxia) were absent, the patient had received ototoxic
medication (such as vinblastine), so it is difficult to define
causality.
Recently, Chae et al. (20) found that PBMCs of APLAID
patients secreted IL-1β after LPS stimulation, while PBMCs
of controls did not, and suggested that systemic inflammation
in APLAID is driven by increased activation of the NLRP3
inflammasome (20). Despite this, the two APLAID patients did
not respond to IL1 blockers (21). In contrast, we report that
levels of IL-1β in whole blood of our patient were decreased
after LPS stimulation (Figure 2). The inefficacy of IL1 blockers
in our patient also argues against the IL-1-driven mechanism of
her disease.
Interestingly, we noticed that levels of IL-10 were substantially
less in whole blood of our patient than in controls. IL-10 is
an immunomodulatory cytokine that is well known to balance
immune response in the gut and impaired signaling in the
IL-10 pathway has been associated with IBD (22). Given that
all APLAID patients have IBD, it is tempting to speculate
that impaired IL-10 production contributes to the immune
dysregulation and is responsible for gut inflammation in these
patients.
In summary, our report shows that a novel heterozygous
missense gain-of-function L848P mutation the PLCG2 gene
causes APLAID in a patient who additionally presented cutis laxa
which appears to extend the APLAID phenotype.
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